The review found that oxcarbazepine was effective as an alternative treatment for refractory partial or generalised epilepsy in children and adults. Given the limited evidence base, limitations in the review process and methodological flaws in the included studies, the authors' conclusion should be treated with caution.
Heterogeneity was assessed by the Χ 2 test and I 2 value. When p<0.1, a random-effects model was used to calculate summary effect measures.
Results of the review
Four RCTs (n=1,095) were included. Three studies compared oxcarbazepine to placebo. One study compared oxcarbazepine to carbamazepine. Studies were considered to be of poor to moderate quality. Three studies had adequate blinding and two studies had adequately described randomisation method, adequate allocation concealment or were free of selective reporting of outcomes. One study was free of other likely bias. Follow-up ranged from 10 to 112 days. There were some discrepancies in the relative risks reported in the text and forest plots (figures presented here were from the forest plots).
In adult patients, oxcarbazepine was associated with a greater chance of a 50% or greater reduction in seizure frequency at all doses: 600mg (RR 2.1, 95% CI 1.3 to 3.4, NNT=7; one trial), 1,200mg (RR 3.2, 95% CI 2.1 to 5.0, NNT=4; one trial) and 2,400mg (RR 3.9, 95% CI 2.6 to 6.0, NNT=3; one trial). The same applied to children who took doses of 30mg to 46mg per day (RR reported in the forest plots 1.9, 95% CI 1.3 to 2.8, NNT=5; one trial).
In adults, oxcarbazepine was associated with a greater chance of no seizures during follow-up at higher doses: 1,200mg (RR 17.6, 95% CI 2.4 to 130.4, NNT not reported; one trial) and 2,400mg (RR 25.4, 95% CI 6.3 to 103.1, NNT=5; two trials). There was no evidence of a difference in absence of seizures when the dose of 600mg of oxcarbazepine was compared to placebo in children on doses of 30mg to 46mg per day.
In adult patients, higher doses of oxcarbazepine were associated with significantly more adverse events than placebo: 1,200mg (RR 1.2, 95% CI 1.1 to 1.3, NNH=7; one trial) and 2,400mg (RR 1.3, 95% CI 1.2 to 1.4, NNH=5; two trials). There was no evidence of significant differences at the lower dose of 600mg of oxcarbazepine in adults or among children who took 30mg to 46mg per day.
Dropout rates from adverse events were significantly higher with higher doses of oxcarbazepine: 1,200mg (RR 4.2, 95% CI 2.5 to 7.0; one trial) and 2,400mg (RR 7.7, 95% CI 4.7 to 12.6; one trial). Dropouts were also significantly higher in children at a dose of 30mg to 46mg per day (RR 3.3, 95% CI 1.1 to 9.7; one trial). There was no evidence of a difference in dropout rates from adverse events with the lower dose (600mg) of oxcarbazepine in adults.
One trial found no evidence of significant differences in outcomes when oxcarbazepine was compared with carbamazepine.
There was no evidence of significant heterogeneity in the one subgroup analysis where two trials were combined.
Authors' conclusions
There was moderate evidence that oxcarbazepine was effective as an alternative treatment for partial or generalised epilepsy in children and adults who were refractory to previous treatment.
CRD commentary
The review question was clearly stated and inclusion criteria appeared appropriate. Four electronic databases and reference lists of retrieved studies were searched for relevant studies. There were no language restrictions Attempts were made to find unpublished studies by searching trial registers. The authors did not describe the methods used for study selection, validity assessment and data extraction, so reviewer error and bias could not be ruled out. The tool used for quality assessment was appropriate, but the included studies were mostly poor to moderate quality. The studies varied in their assessment of therapeutic response. Follow-up was short in most of the studies. Results of individual studies were displayed in forest plots in separate subgroups according to population (adults or children) and dose of oxcarbazepine; synthesis was possible for only two studies of oxcarbazepine 2,400mg that assessed adverse events and freedom from seizures.
